1. **Name and Address of Reporting Person**
   
   Konstantinovsky Irina

   (Last)  (First)  (Middle)
   
   C/O HORIZON THERAPEUTICS PLC
   CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
   
   DUBLIN  L2  4

   (Street)  (City)  (State)  (Zip)

2. **Issuer Name and Ticker or Trading Symbol**
   
   Horizon Therapeutics Public Ltd Co [ HZNP ]

3. **Date of Earliest Transaction (Month/Day/Year)**
   
   05/06/2020

4. **If Amendment, Date of Original Filed (Month/Day/Year)**
   
   05/07/2020

5. **Relationship of Reporting Person(s) to Issuer (Check all applicable)**
   
   X Director
   
   10% Owner
   
   X Officer (give title below)
   
   EVP, Chief Human Resources Off

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Amount (A) or (D)</th>
<th>Price</th>
<th>Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Shares</td>
<td>05/06/2020</td>
<td></td>
<td>M</td>
<td>59,794 A</td>
<td>$14.05</td>
<td>95,183</td>
<td>D</td>
<td>Direct</td>
<td>10% Owner</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>05/07/2020</td>
<td></td>
<td>D</td>
<td>59,794 D</td>
<td>$41.19</td>
<td>35,389</td>
<td>D</td>
<td>Indirect</td>
<td>EVP, Chief Human Resources Off</td>
</tr>
</tbody>
</table>

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price or Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Transaction Code (Instr. 8)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>Title and Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>Price of Derivative Security (Instr. 5)</th>
<th>Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Option (Right to Buy)</td>
<td>$14.05</td>
<td>05/06/2020</td>
<td></td>
<td>M</td>
<td>(A) 59,794</td>
<td>(2) 09/10/2027</td>
<td>Ordinary Shares 59,794 $0.00 71,812 D</td>
<td>Indirect</td>
<td>Direct</td>
<td>EVP, Chief Human Resources Off</td>
<td>10% Owner</td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 3, 2020.
2. 25% of the 131,606 shares originally subject to the stock option vested and became exercisable on September 11, 2018, and remaining shares vest in equal monthly installments thereafter.

**Remarks:**

/\ Miles W. McHugh, 05/07/2020

Attorney-in-Fact

** Signature of Reporting Person Date **

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.